$247 Million is the total value of SILVERARC CAPITAL MANAGEMENT, LLC's 71 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was 100.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| CBIO | Exit | CATALYST BIOSCIENCES INC | $0 | – | -10,000 | -100.0% | -0.02% | – |
| Exit | ADAGIO THERAPEUTICS INC | $0 | – | -5,000 | -100.0% | -0.12% | – | |
| AFMD | Exit | AFFIMED N V | $0 | – | -47,182 | -100.0% | -0.16% | – |
| ARCT | Exit | ARCTURUS THERAPEUTICS HLDGS | $0 | – | -6,208 | -100.0% | -0.17% | – |
| RAPT | Exit | RAPT THERAPEUTICS INC | $0 | – | -11,796 | -100.0% | -0.21% | – |
| SURF | Exit | SURFACE ONCOLOGY INC | $0 | – | -50,000 | -100.0% | -0.21% | – |
| KROS | Exit | KEROS THERAPEUTICS INC | $0 | – | -10,000 | -100.0% | -0.22% | – |
| EVLO | Exit | EVELO BIOSCIENCES INCput | $0 | – | -61,700 | -100.0% | -0.24% | – |
| AYLA | Exit | AYALA PHARMACEUTICALS INC | $0 | – | -40,956 | -100.0% | -0.26% | – |
| CRIS | Exit | CURIS INC | $0 | – | -62,070 | -100.0% | -0.28% | – |
| ISEE | Exit | IVERIC BIO INC | $0 | – | -30,000 | -100.0% | -0.28% | – |
| CABA | Exit | CABALETTA BIO INC | $0 | – | -42,022 | -100.0% | -0.29% | – |
| GH | Exit | GUARDANT HEALTH INC | $0 | – | -4,218 | -100.0% | -0.30% | – |
| CLXPF | Exit | CYBIN INC | $0 | – | -250,000 | -100.0% | -0.31% | – |
| DRNA | Exit | DICERNA PHARMACEUTICALS INC | $0 | – | -31,040 | -100.0% | -0.35% | – |
| NTLA | Exit | INTELLIA THERAPEUTICS INC | $0 | – | -4,950 | -100.0% | -0.38% | – |
| RNLX | Exit | RENALYTIX PLCads | $0 | – | -37,000 | -100.0% | -0.42% | – |
| ATHA | Exit | ATHIRA PHARMA INC | $0 | – | -106,388 | -100.0% | -0.56% | – |
| ARNA | Exit | ARENA PHARMACEUTICALS INC | $0 | – | -18,581 | -100.0% | -0.62% | – |
| ADMS | Exit | ADAMAS PHARMACEUTICALS INC | $0 | – | -288,042 | -100.0% | -0.80% | – |
| ZNTL | Exit | ZENTALIS PHARMACEUTICALS INC | $0 | – | -23,855 | -100.0% | -0.90% | – |
| Exit | ERASCA INC | $0 | – | -93,122 | -100.0% | -1.12% | – | |
| CCXI | Exit | CHEMOCENTRYX INCput | $0 | – | -139,200 | -100.0% | -1.35% | – |
| ARVN | Exit | ARVINAS INC | $0 | – | -37,249 | -100.0% | -1.73% | – |
| FULC | Exit | FULCRUM THERAPEUTICS INC | $0 | – | -185,691 | -100.0% | -2.96% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2022-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| INTRA-CELLULAR THERAPIES INC | 12 | Q3 2023 | 7.8% |
| IMMUNOGEN INC | 12 | Q3 2023 | 8.3% |
| Morphic Holding Inc | 12 | Q3 2023 | 4.5% |
| UNUM THERAPEUTICS INC | 12 | Q3 2023 | 3.2% |
| INSMED INC | 12 | Q3 2023 | 3.5% |
| UNITED THERAPEUTICS CORP DEL | 12 | Q3 2023 | 2.2% |
| MERUS N V | 11 | Q3 2023 | 5.1% |
| VERACYTE INC | 11 | Q3 2023 | 4.9% |
| EVOGENE LTD | 11 | Q3 2023 | 1.6% |
| COMPUGEN LTD | 11 | Q3 2023 | 1.1% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Benitec Biopharma Inc.Sold out | February 08, 2023 | 0 | 0.0% |
| DELCATH SYSTEMS, INC.Sold out | February 08, 2022 | 0 | 0.0% |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| SC 13G | 2024-02-14 |
| 13F-HR | 2023-11-13 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
| SC 13G/A | 2023-02-08 |
| 13F-HR | 2022-10-28 |
View SILVERARC CAPITAL MANAGEMENT, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.